Replication of a pre-existing resistant HIV-1 subpopulation in vivo vivo after introduction of a strong selective drug pressure

Antiviral Therapy

Volumn 1, Issue 1, 1996, Pages 33-41

  De Jong, Menno D ^a,b   Schuurman, Rob ^a   Lange, Joep M A ^a   Boucher, Charles A B ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TYROSINE; VIRUS RNA;

ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD; CODON; DRUG EFFECT; FOLLOW UP; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MUTATION; POLYMERASE CHAIN REACTION; PROVIRUS; VIRUS LOAD;

CODON; CYSTEINE; DRUG RESISTANCE, MICROBIAL; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; NEVIRAPINE; POLYMERASE CHAIN REACTION; PROVIRUSES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TYROSINE; VIRAL LOAD;

EID: 0029677211     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen PME & van der Noordaa J. A rapid and simple method for the purification of nucleic acids. Journal of Clinical Microbiology 1990; 28:495-503.
2. Boucher CAB, van Leeuwen R, Kellam P, Schipper P, Tijnagel J, Lange JMA & Larder BA. Effect of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrobial Agents & Chemotherapy 1993; 37:1525-1530.
3. Brun-Vézinet F, Ingrand D, Deforges L, Gochi K, Ferchal F, Schmitt MP, Jung M, Masquelier B, Aubert J, Buffet-Janvresse C & Fleury H. HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. Journal of Virological Methods 1992; 37:177-188.
4. Coffin JM. HIV population dynamics in vivo implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-489.
5. Cohen KA, Hopkins J, Ingraham RH, Pargellis C, Wu JC, Palladino DE, Kinkade, P, Warren TC, Rogers S & Adams J. Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type 1 reverse transcriptase. Journal of Biological Chemistry 1991; 266:14670-14674.
6. Condra JH, Emini EA, Gotlib L, Graham DJ, Schlabach AJ, Wolfgang JA, Colonna RJ & Sardana W. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrobial Agents & Chemotherapy 1992; 36:1441-1446.
7. Conlon CP, Klenerman P, Edwards A, Larder BA & Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. Journal of Infections Diseases 1994; 169:411-415.
8. De Jong MD, Loewenthal M, Boucher CAB, van der Ende I, Hall D, Schipper P, Imrie A, Weigel HM, Kauffmann RH, Koster R, Seville P, Rocklin R, Cooper DA & Lange JMA. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. Journal of Infectious Diseases 1994; 169:1346-1350.
9. Erice A, Mayers DL, Strike DG, Sannerud KJ, McCutchan FE, Henry K & Balfour Jr HH. Primary infection with zidovudine-resistant human immunodeficiency virus rype-1. New England Journal of Medicine 1993; 328:1163-1165.
10. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM & Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, London 1995; 373:123-126.
11. Kaye S, Loveday C & Tedder RS. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type 1-infected patients treated with zidovudine. Journal of Medical Virology 1992; 37:241-246.
12. Kellam P & Larder BA. Recombinant virus assay: a rapid phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrobial Agents & Chemotherapy 1994; 38:23-30.
13. Kohlstaedt LA, Wang J, Friedman JM, Rice PA & Steitz TA. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256:1783-1790.
14. Koup RA, Merluzzi VJ, Hargrave KD, Adams J, Grozinger K, Eckner RJ & Sullivan JL. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. Journal of Infectious Diseases 1991; 163:966-970.
15. Larder BA. 3′-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrobial Agents & Chemotherapy 1992; 36:2664-2669.
16. Larder BA & Boucher CAB. PCR detection of human immunodeficiency virus drug resistance mutations. In Diagnostic molecular microbiology: principles and applications. Edited by DH Persing, TF Smith, EC Tenover & TJ White. 1993; pp527-533. Washington: American Society of Microbiology.
17. Larder BA, Chesebro B & Richman DD. Susceptibilities of zidovudine-susceptible and resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrobial Agents & Chemotherapy 1990; 34:436-441.
18. Mellors JW, Dutschman GE, Im GJ, Tramontano E, Winkler SR & Cheng YC. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to nonnucleoside inhibitors of reverse transcriptase. Molecular Pharmacology 1992: 41:446-451.
19. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J, Rosenthal AS, Faanes R, Eckner RJ, Koup RA & Sullivan JL. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990; 250:1411-1413.
20. Mohri H, Singh MK, Ching WTW & Ho DD. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proceedings of the National Academy of Sciences, USA 1993; 90:25-29.
21. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L & Kwok S. Rapid and simple PCR assay for quantification of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. Journal of Clinical Microbiology 1994; 32:292-300.
22. Myers G, Korber B, Wain-Hobson S, Smith RF & Pavlakis GN. Human retroviruses and AIDS. 1993. Los Alamos National Laboratory, Los Alamos, New Mexico.
23. Najera I, Richman DD, Olivares I, Rojas JM, Peinado MA, Perucho M, Najera R & López-Galíndez C. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Research and Human Retrofiruses 1994; 10:1479-1488.
24. Preston BD, Poiesz BJ & Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242:1168-1171.
25. Richman DD, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S & Griffin J. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proceedings of the National Academy of Sciences, USA 1991; 88:11241-11245.
26. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D, Shih CK, Myers M & Griffin J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Journal of Virology 1994; 68:661-666.
27. Rocancourt D, Bonnerot C, Jouin H, Emerman M & Nicolas J F. Activation of a β-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-1 infected cells. Journal of Virology 1990; 64:2660-2668.
28. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, Kwok S, Sninsky J & Boucher CAB. Rapid changes in human immunodeficiency virus 1-RNA load and appearance of drug resistance mutations in individuals treated with lamivudine. Journal of Infections Diseases 1995; 171:1411-1419.
29. Shih CK, Rose JM, Hansen GL, Wu JC, Bacolla A & Griffin JA. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptase display reversed sensitivity to nonnucleoside analog inhibitors. Proceedings of the National Academy of Sciences, USA 1991; 88:9878-9882.
30. Smerdon SJ, Jager J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA & Steitz TA. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences, USA 1994; 91:3911-3915.
31. Vanden Haesevelde M, Decourt JL, De Leys RJ, Vanderborght B, van der Groen G, van Heuverswijn H & Saman E. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. Journal of Virology 1994; 68:1586-1596.
32. Veenstra J, Schuurman R, Cornelissen M, Van 't Wout AB, Boucher CAB, Schuitemaker H, Goudsmit J & Coutinho RA. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clinical Infections Diseases 1995; 21:556-560.
33. Wahlberg J, Fiore J, Angarano G, Uhlen M & Albert J. Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type 1 variants. Journal of Infections Diseases 1994; 169:611-614.
34. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS & Shaw GM. Viral dynamics in human immunodeficiency virus type 1 infection. Nature, London 1995; 373:117-122.